CAR-T and other adoptive cell therapies for B cell malignancies

Peihua Lu; Holly A. Hill; Lucy J. Navsaria; Michael L. Wang

doi:10.1016/j.jncc.2021.07.001

CAR-T and other adoptive cell therapies for B cell malignancies

Peihua Lu, Holly A. Hill, Lucy J. Navsaria, Michael L. Wang

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in constructs of CAR-T have improved specificity in targeting malignant cells. Multiple clinical trials have demonstrated the efficacy of CAR-T and other cellular treatments. In spite of advances in cellular therapies, hurdles in managing toxicities and lingering resistance remain. This review aims to summarize current innovations in adoptive cellular therapies and introduces future paths of discovery that will enhance these therapies in the era of precision oncology.

Original language	English (US)
Pages (from-to)	88-96
Number of pages	9
Journal	Journal of the National Cancer Center
Volume	1
Issue number	3
DOIs	https://doi.org/10.1016/j.jncc.2021.07.001
State	Published - Sep 2021

Keywords

Adoptive cell therapy
B cell malignancies
Chimeric antigen receptor

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.jncc.2021.07.001

Cite this

@article{b2ff7620794144d8aced487ecda70866,

title = "CAR-T and other adoptive cell therapies for B cell malignancies",

abstract = "B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in constructs of CAR-T have improved specificity in targeting malignant cells. Multiple clinical trials have demonstrated the efficacy of CAR-T and other cellular treatments. In spite of advances in cellular therapies, hurdles in managing toxicities and lingering resistance remain. This review aims to summarize current innovations in adoptive cellular therapies and introduces future paths of discovery that will enhance these therapies in the era of precision oncology.",

keywords = "Adoptive cell therapy, B cell malignancies, Chimeric antigen receptor",

author = "Peihua Lu and Hill, {Holly A.} and Navsaria, {Lucy J.} and Wang, {Michael L.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

doi = "10.1016/j.jncc.2021.07.001",

language = "English (US)",

volume = "1",

pages = "88--96",

journal = "Journal of the National Cancer Center",

issn = "2096-8663",

publisher = "Chinese National Cancer Center",

number = "3",

}

TY - JOUR

T1 - CAR-T and other adoptive cell therapies for B cell malignancies

AU - Lu, Peihua

AU - Hill, Holly A.

AU - Navsaria, Lucy J.

AU - Wang, Michael L.

PY - 2021/9

Y1 - 2021/9

N2 - B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in constructs of CAR-T have improved specificity in targeting malignant cells. Multiple clinical trials have demonstrated the efficacy of CAR-T and other cellular treatments. In spite of advances in cellular therapies, hurdles in managing toxicities and lingering resistance remain. This review aims to summarize current innovations in adoptive cellular therapies and introduces future paths of discovery that will enhance these therapies in the era of precision oncology.

AB - B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in constructs of CAR-T have improved specificity in targeting malignant cells. Multiple clinical trials have demonstrated the efficacy of CAR-T and other cellular treatments. In spite of advances in cellular therapies, hurdles in managing toxicities and lingering resistance remain. This review aims to summarize current innovations in adoptive cellular therapies and introduces future paths of discovery that will enhance these therapies in the era of precision oncology.

KW - Adoptive cell therapy

KW - B cell malignancies

KW - Chimeric antigen receptor

UR - http://www.scopus.com/inward/record.url?scp=85133148943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133148943&partnerID=8YFLogxK

U2 - 10.1016/j.jncc.2021.07.001

DO - 10.1016/j.jncc.2021.07.001

M3 - Review article

AN - SCOPUS:85133148943

SN - 2096-8663

VL - 1

SP - 88

EP - 96

JO - Journal of the National Cancer Center

JF - Journal of the National Cancer Center

IS - 3

ER -

CAR-T and other adoptive cell therapies for B cell malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this